MENU
GNOM
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

GNOM stock forecast, quote, news & analysis

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index")... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
GNOM
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for GNOM with price predictions
Oct 16, 2026

Momentum Indicator for GNOM turns negative, indicating new downward trend

GNOM saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned negative. In 96 of the 101 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GNOM moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Moving Average Convergence Divergence Histogram (MACD) for GNOM turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 52 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

GNOM moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

GNOM broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in 224 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

The Aroon Indicator entered an Uptrend today. In 181 of 194 cases where GNOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Global X Genomics & Biotechnology ETF (GNOM) ETF is 29.91B. The market cap for tickers in the group ranges from 131.87M to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is CRBU at 131.87M.

High and low price notable news

The average weekly price growth across all stocks in the Global X Genomics & Biotechnology ETF (GNOM) ETF was -6%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 36%. LLY experienced the highest price growth at 7%, while PACB experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Global X Genomics & Biotechnology ETF (GNOM) ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was 18% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 62
Price Growth Rating: 54
SMR Rating: 83
Profit Risk Rating: 91
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
GNOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
Global X Funds600 Lexington Avenue, 20th FloorNew York
Phone
+1 8884938631
Web
www.globalxfunds.com
Momentum Indicator for GNOM turns negative, indicating new downward trend